Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type
- PMID: 630211
- PMCID: PMC1603216
- DOI: 10.1136/bmj.1.6112.533
Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type
Abstract
Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil. The complete remission rate was higher in the group receiving combination chemotherapy, but the overall response rate was the same for both groups. The mean duration of complete remission was the same as that of good partial remission, and was the same for both treatments. The duration of remission was influenced by histological type and extent of disease at presentation, but not age. Those who responded to the initial treatment (whether with complete or with good partial remission) survived significantly longer than did non-responders. It is concluded that neither treatment is satisfactory and that new treatment programmes are needed for patients with a favourable prognosis, especially young patients with extensive disease.
Similar articles
-
Chemotherapy of malignant lymphoma.Ann Acad Med Singap. 1981 Jul;10(3):281-7. Ann Acad Med Singap. 1981. PMID: 7332296
-
Chemotherapy in the management of stage III/IV grade 1 non-Hodgkin's lymphomas (Report no 17).Clin Radiol. 1981 Sep;32(5):547-52. doi: 10.1016/s0009-9260(81)80185-7. Clin Radiol. 1981. PMID: 7023798 Clinical Trial.
-
[Therapy of malignant non-Hodgkin's lymphoma].Z Gesamte Inn Med. 1979 Apr 1;34(7):208-12. Z Gesamte Inn Med. 1979. PMID: 582641 German.
-
Chemotherapy of the non-Hodgkin's lymphomas.Med Clin North Am. 1976 Sep;60(5):1043-52. doi: 10.1016/s0025-7125(16)31847-8. Med Clin North Am. 1976. PMID: 59842 Review. No abstract available.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
-
A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma.Cancer Chemother Pharmacol. 1986;18(1):54-8. doi: 10.1007/BF00253065. Cancer Chemother Pharmacol. 1986. PMID: 3757160
-
Low-grade lymphomas: new entities and treatment concepts.Med Oncol. 1995 Sep;12(3):131-42. doi: 10.1007/BF01571190. Med Oncol. 1995. PMID: 8852395 Review.
-
In vitro testing of calcium channel blockers and cytotoxic chemotherapy in B-cell low-grade non-Hodgkin's lymphoma.Br J Cancer. 1998 May;77(10):1598-603. doi: 10.1038/bjc.1998.262. Br J Cancer. 1998. PMID: 9635834 Free PMC article.
-
Chlorambucil and interferon for low grade non-Hodgkin's lymphoma.Br J Cancer. 1987 Feb;55(2):225-6. doi: 10.1038/bjc.1987.42. Br J Cancer. 1987. PMID: 3814493 Free PMC article. No abstract available.
-
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.Invest New Drugs. 1991 Feb;9(1):79-82. doi: 10.1007/BF00194551. Invest New Drugs. 1991. PMID: 1827434 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources